- Home
- / Jacobio
Jacobio
Stock Price
$6.8
2023-05-22
Market Capitalization
$5.2 B
2023-05-22
Revenue
¥95.7 M
FY, 2022
Jacobio Summary
Company summary
- Overview
- Jacobio Pharmaceuticals Group (北京加科思新药研发有限公司, formerly known as Jacobio (Cay) Pharmaceuticals) is a pharmaceutical company that provides therapy solutions. It develops drugs and monoclonal antibodies for cancer treatments and conventional antibody-drug conjugates (ADCs).
- Type
- Public
- Status
- Active
- Founded
- 2015
- HQ
- Beijing, CN | view all locations
- Cybersecurity rating
Key people
Wang Xiaojie, President of Administration
Hu Yunyan, Executive Vice President
Long Wei, Executive Vice President, Preclinical R&D
LocationsView all
5 locations detected
Beijing, Bei Jing Shi HQ
China
Building F2, 88 Kechuang, 6th St.
Lexington, MA
United States
99 Hayden Ave
Beijing, Bei Jing Shi
China
Room 1209, block A, Shoudong international, building 5
Beijing, Beijing
China
Suite 2105, Building T2, Dazu Square
Shanghai, Shang Hai Shi
China
595 North Caoxi Road Building A Suite 6009
Jacobio Financials
Summary financials
- Revenue (FY, 2022)
- ¥95.7M
- Gross profit (FY, 2022)
- ¥28.3M
- Net income (FY, 2022)
- (¥371.9M)
- Cash (FY, 2022)
- ¥1.3B
- EBIT (FY, 2022)
- (¥394.2M)
- Enterprise value
- $4.0B